Logo

ENTO

Entero Therapeutics, Inc.

ENTO

Entero Therapeutics, Inc. • NASDAQ
$2.99 ▲ 5.28% (+0.15)
Market Cap $14.25 M
52w High $5.84
52w Low $0.97
Dividend Yield 0%
P/E -0.26
Volume 621.70K
Outstanding Shares 4.77M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $934.787K ▲ $-1.153M ▼ 0% $-0.75 ▼ $-934.787K ▼
Q2-2025 $0 $638.864K ▼ $-998.271K ▲ 0% $-0.21 ▲ $-638.864K ▲
Q1-2025 $0 $821.386K ▼ $-1.26M ▲ 0% $-0.28 ▲ $-930.203K ▲
Q4-2024 $0 $1.204M ▼ $-12.238M ▼ 0% $-2.57 ▼ $-1.204M ▲
Q3-2024 $0 $1.893M $-2.581M 0% $-0.57 $-1.891M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.517M ▲ $135.37M ▲ $45.808M ▲ $27.881M ▼
Q2-2025 $4.474K ▼ $85.059M ▼ $29.676M ▲ $55.383M ▼
Q1-2025 $59.352K ▼ $85.204M ▼ $28.74M ▲ $56.463M ▼
Q4-2024 $163.476K ▼ $85.41M ▼ $27.605M ▲ $57.804M ▼
Q3-2024 $366.788K $85.821M $15.771M $70.05M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-1.153M ▼ $-855.688K ▼ $336.427K ▲ $3.025M ▲ $2.506M ▲ $-855.688K ▼
Q2-2025 $-998.27K ▲ $-54.878K ▲ $0 $0 ▼ $-54.878K ▲ $-54.878K ▲
Q1-2025 $-1.26M ▲ $-818.635K ▼ $0 $700K ▲ $-118.635K ▲ $-818.635K ▼
Q4-2024 $-12.238M ▼ $-171.518K ▲ $0 $-31.798K ▼ $-203.316K ▲ $-171.518K ▲
Q3-2024 $-2.581M $-1.848M $0 $1.553M $-295.687K $-1.848M

Five-Year Company Overview

Income Statement

Income Statement Entero has effectively been a pre-revenue company for the entire period shown. There is no meaningful sales activity yet, either from the legacy biotech business or the newer AI energy focus. Expenses have been higher than income every year, so the company has been consistently loss-making. The losses themselves are relatively small in absolute terms, but because they are spread over a very tiny equity base and share count that has repeatedly changed, the per-share figures look extreme and volatile. Overall, this is still an early-stage story with no proven commercial earnings engine in place.

Balance Sheet

Balance Sheet The balance sheet is very light. The company holds only a small pool of assets and cash, with no debt on the books, and equity hovering around break-even for several years before turning modestly positive more recently. That suggests repeated recapitalizations, reverse splits, and restructuring to keep the company afloat. The absence of debt reduces financial pressure from lenders, but the small asset and equity base also mean there is limited cushion if plans take longer than expected or costs rise. This is a thin financial foundation for an ambitious dual business model.

Cash Flow

Cash Flow Cash is consistently flowing out of the business rather than in. Operating cash flows have been negative each year, reflecting ongoing spending on overhead, development, and corporate costs without offsetting revenue. Investment spending is minimal, so free cash flow is essentially just a mirror of the operating burn. The size of the burn appears modest in absolute terms, but given how small the company is, it likely still requires periodic capital raises to fund operations. Sustainability will depend on continued access to external financing until either the AI energy platform or the drug pipeline begins to generate meaningful cash.

Competitive Edge

Competitive Edge Competitively, Entero sits in a very unusual spot. It is trying to build a position in two demanding arenas at once: AI-powered grid and data-center energy management, and gastrointestinal drug development. In AI energy, the company’s Grid AI platform is targeting a real and growing bottleneck—power for AI data centers and distributed energy resources. That focus is differentiated, but the field is crowded with utilities, software firms, and industrial players all trying to solve similar problems. Entero’s early partnerships and specialized orchestration technology could help it carve out a niche, but it is still at an early, unproven stage with no visible recurring revenue base yet. In biotech, the GI pipeline targets areas with real unmet medical need and potentially attractive markets (celiac disease, gastroparesis, exocrine pancreatic insufficiency). However, these programs compete against both existing standards of care and other emerging therapies, and they must still navigate lengthy, expensive clinical and regulatory paths. Overall, the company’s competitive position is more about long-term potential than current market power, and it faces intense execution risk in both verticals.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of Entero. On the AI energy side, Grid AI’s orchestration platform, dynamic load management, and virtual power plant capabilities are designed specifically for a world of hyperscale data centers and increasingly electrified grids. The strategy leans heavily on software, AI, and edge analytics, which can scale if the technology proves effective and the company wins major customers. On the biotech side, the GI pipeline reflects years of specialized R&D. A potential first-in-class therapy for celiac disease, new approaches for gastroparesis, and a non-animal enzyme therapy for pancreatic insufficiency all address meaningful patient needs. Each program carries typical biotech risks—clinical setbacks, regulatory hurdles, and high costs—but also offers the potential for differentiated products if the data are supportive. The key challenge is that Entero is now a hybrid innovator, splitting attention between two very different R&D cultures and timelines. Success will depend on disciplined prioritization, smart partnering (especially for later-stage drug development), and continued advancement of the AI platform from concept and pilots to scaled deployments.

Summary

Entero Therapeutics is in the middle of a radical transformation. Historically a tiny, loss-making biotech with no revenue but a focused GI pipeline, it has now shifted its center of gravity toward AI-driven energy infrastructure via the Grid AI acquisition. Financially, the company remains pre-revenue, runs a steady cash burn, and operates on a very thin balance sheet with no debt but limited resources, implying ongoing reliance on outside capital. Strategically, the company is aiming at two big opportunity sets: solving power bottlenecks for AI data centers and modern grids, and addressing major unmet medical needs in gastrointestinal diseases. Both areas are rich with potential but also fraught with technical, regulatory, and execution risk, and both are crowded with capable competitors. In practical terms, Entero today is a high-uncertainty, early-stage platform: strong on ideas and innovation, weak on current financial strength and commercial proof. The story from here will hinge on whether management can secure meaningful AI energy contracts, advance and/or partner its GI drug candidates, and keep funding in place long enough to turn either of these innovation tracks into durable revenue and cash flow.

NEWS

November 28, 2025 · 8:00 AM UTC

Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"

Read more

November 19, 2025 · 8:45 AM UTC

ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer

Read more

November 13, 2025 · 8:35 AM UTC

Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy

Read more

November 6, 2025 · 8:45 AM UTC

Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid

Read more

October 30, 2025 · 9:00 AM UTC

Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)

Read more